Literature DB >> 18995946

Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review.

Lidia Rosi Medeiros1, Daniela Dornelles Rosa, Maria Inês da Rosa, Mary Clarisse Bozzetti.   

Abstract

A quantitative systematic review was performed to estimate the accuracy of CA 125 assay in the diagnosis of ovarian tumors. Studies that evaluated CA 125 levels for the diagnosis of ovarian tumors and compared them with paraffin-embedded sections as the diagnostic standard were included. Seventeen studies were analyzed, which included 2374 women. The pooled sensitivity for the diagnosis of borderline tumors or ovarian cancer was 0.80 (I.C. 95% 0.76-0.82) and the specificity was 0.75 (I.C. 95% 0.73-0.77). The diagnostic odds ratio for ovarian cancer and borderline lesions vs. benign lesions was 21.2 (95% C.I., 12-37). Summary receiver operating characteristic curves were constructed due to heterogeneity in the diagnostic odds ratio. For malignant and borderline ovarian tumors vs. benign lesions the area under the curve was 0.8877. A CA 125 level of >or= 35 U/ml is a useful preoperative test for predicting the benign or malignant nature of pelvic masses. The accuracy of CA 125 in the diagnosis of ovarian tumors is high and very important in helping the surgeon to decide what kind of surgery should be performed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18995946     DOI: 10.1016/j.ejogrb.2008.08.011

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  32 in total

1.  Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.

Authors:  Teresa Granato; Cecilia Midulla; Flavia Longo; Barbara Colaprisca; Luigi Frati; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-04-13

2.  Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.

Authors:  Douglas D Taylor; Cicek Gercel-Taylor; Lynn P Parker
Journal:  Gynecol Oncol       Date:  2009-07-31       Impact factor: 5.482

3.  CA 125 and other tumor markers in uterine leiomyomas and their association with lesion characteristics.

Authors:  Ali Babacan; Cem Kizilaslan; Ismet Gun; Murat Muhcu; Ercument Mungen; Vedat Atay
Journal:  Int J Clin Exp Med       Date:  2014-04-15

4.  A Case of Meigs' Syndrome: The (18)F-FDG PET/CT Findings.

Authors:  Eun Seong Lee; Tae-Sung Kim; Chong Woo Yoo; Sang-Soo Seo; Seok-Ki Kim
Journal:  Nucl Med Mol Imaging       Date:  2011-07-15

5.  Identification of novel serum biomarkers in child nephroblastoma using proteomics technology.

Authors:  Qian Zhang; Jiaxiang Wang; Rui Dong; Shaobo Yang; Shu Zheng
Journal:  Mol Biol Rep       Date:  2010-04-06       Impact factor: 2.316

6.  HE4: a new potential early biomarker for the recurrence of ovarian cancer.

Authors:  Emanuela Anastasi; Giulia Giovanna Marchei; Valentina Viggiani; Giuseppina Gennarini; Luigi Frati; Maria Gabriella Reale
Journal:  Tumour Biol       Date:  2010-01-23

7.  HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma.

Authors:  Cecilia Midulla; Lucia Manganaro; Flavia Longo; Valentina Viggiani; Luigi Frati; Teresa Granato; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-03-20

Review 8.  Hydropic leiomyoma presenting as a rare condition of pseudo-Meigs syndrome: literature review and a case of a pseudo-Meigs syndrome mimicking ovarian carcinoma with elevated CA125.

Authors:  Mehrnoosh Pauls; Heather MacKenzie; Ravi Ramjeesingh
Journal:  BMJ Case Rep       Date:  2019-01-10

9.  Correlation of cytohistlogical expression and serum level of ca125 in ovarian neoplasm.

Authors:  Chhanda Das; Madhumita Mukhopadhyay; Tarun Ghosh; Ashis Kumar Saha; Moumita Sengupta
Journal:  J Clin Diagn Res       Date:  2014-03-15

10.  Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors.

Authors:  Rafał Watrowski; Georg Heinze; Christoph Jäger; Johannes Forster; Robert Zeillinger
Journal:  Tumour Biol       Date:  2016-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.